Literature DB >> 19910422

A comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in pulmonary neuroendocrine tumors.

Irfan Kayani1, Brendon G Conry, Ashley M Groves, Thida Win, John Dickson, Martyn Caplin, Jamshed B Bomanji.   

Abstract

UNLABELLED: Our purpose was to compare the performance of (68)Ga-1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid-d-Phe(1),Tyr(3)-octreotate (DOTATATE), a novel selective somatostatin receptor 2 PET ligand, and (18)F-FDG in the detection of pulmonary neuroendocrine tumors using PET/CT, with correlation of uptake and tumor grade on histology.
METHODS: The imaging findings of the first 18 consecutive patients (8 men and 10 women) with pulmonary neuroendocrine tumors (11 typical carcinoids, 2 atypical carcinoids, 1 large cell neuroendocrine tumor, 1 small cell neuroendocrine carcinoma, 1 non-small cell lung cancer with neuroendocrine differentiation, and 2 cases of diffuse idiopathic pulmonary neuroendocrine cell hyperplasia) who underwent (68)Ga-DOTATATE and (18)F-FDG PET/CT were reviewed. In all cases, the diagnosis was established on histology.
RESULTS: Of 18 patients, 15 had primary tumors (median size, 2.7 cm; range, 0.5-8 cm) and 3 had recurrent tumors. All typical carcinoids showed high uptake of (68)Ga-DOTATATE (maximum standardized uptake value [SUV(max)] >or= 8.2), but 4 of 11 showed negative or minimal (18)F-FDG uptake (SUV(max) = 1.7-2.9). All tumors of higher grade showed high uptake of (18)F-FDG (SUV(max) >or= 11.7), but 3 of 5 showed only minimal accumulation of (68)Ga-DOTATATE (SUV(max) = 2.2-2.8). Neither case of diffuse idiopathic pulmonary neuroendocrine cell hyperplasia showed uptake of (68)Ga-DOTATATE or (18)F-FDG. Typical carcinoids showed significantly higher uptake of (68)Ga-DOTATATE and significantly less uptake of (18)F-FDG than did tumors of higher grade (P = 0.002 and 0.005). There was no instance of false-positive uptake of (68)Ga-DOTATATE, but there were 3 sites of (18)F-FDG uptake secondary to inflammation. (68)Ga-DOTATATE was superior to (18)F-FDG in discriminating endobronchial tumor from distal collapsed lung (P = 0.02).
CONCLUSION: Typical bronchial carcinoids showed higher and more selective uptake of (68)Ga-DOTATATE than of (18)F-FDG. Atypical carcinoids and higher grades had less (68)Ga-DOTATATE avidity but were (18)F-FDG-avid.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19910422     DOI: 10.2967/jnumed.109.066639

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  57 in total

1.  Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE.

Authors:  Irene Virgolini; Valentina Ambrosini; Jamshed B Bomanji; Richard P Baum; Stefano Fanti; Michael Gabriel; Nikolaos D Papathanasiou; Giovanna Pepe; Wim Oyen; Clemens De Cristoforo; Arturo Chiti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-10       Impact factor: 9.236

2.  Role of (68)Ga-DOTATOC PET/CT in the evaluation of primary pulmonary carcinoids.

Authors:  Tarun Jindal; Arvind Kumar; Balasubramanian Venkitaraman; Roman Dutta; Rakesh Kumar
Journal:  Korean J Intern Med       Date:  2010-11-27       Impact factor: 2.884

Review 3.  Diagnostic utility of Gallium-68-somatostatin receptor PET/CT in ectopic ACTH-secreting tumors: a systematic literature review and single-center clinical experience.

Authors:  Elena Varlamov; José Miguel Hinojosa-Amaya; Madeleine Stack; Maria Fleseriu
Journal:  Pituitary       Date:  2019-10       Impact factor: 4.107

Review 4.  PET/CT assessment of neuroendocrine tumors of the lung with special emphasis on bronchial carcinoids.

Authors:  Filippo Lococo; Alfredo Cesario; Massimiliano Paci; Angelina Filice; Annibale Versari; Cristian Rapicetta; Tommaso Ricchetti; Giorgio Sgarbi; Marco Alifano; Alberto Cavazza; Giorgio Treglia
Journal:  Tumour Biol       Date:  2014-05-22

5.  Evolving role of PET/CT with different tracers in the evaluation of pulmonary neuroendocrine tumours.

Authors:  Giorgio Treglia; Luca Giovanella; Filippo Lococo
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-02-21       Impact factor: 9.236

Review 6.  The value of (68)Ga-DOTATATE PET/CT in diagnosis and management of neuroendocrine tumors compared to current FDA approved imaging modalities: a review of literature.

Authors:  Alireza Mojtahedi; Sanjay Thamake; Izabela Tworowska; David Ranganathan; Ebrahim S Delpassand
Journal:  Am J Nucl Med Mol Imaging       Date:  2014-08-15

7.  Non-functioning gastroenteropancreatic (GEP) tumors: a 111In-Pentetreotide SPECT/CT diagnostic study.

Authors:  Angela Spanu; Orazio Schillaci; Bastiana Piras; Diego F Calvisi; Antonio Falchi; Roberta Danieli; Susanna Nuvoli; Franca Dore; Giuseppe Madeddu
Journal:  Am J Nucl Med Mol Imaging       Date:  2017-09-01

Review 8.  Peptide-based imaging agents for cancer detection.

Authors:  Xiaolian Sun; Yesen Li; Ting Liu; Zijing Li; Xianzhong Zhang; Xiaoyuan Chen
Journal:  Adv Drug Deliv Rev       Date:  2016-06-18       Impact factor: 15.470

9.  Long-term results of PRRT in advanced bronchopulmonary carcinoid.

Authors:  Annapaola Mariniello; Lisa Bodei; Carmine Tinelli; Silvia Melania Baio; Laura Gilardi; Marzia Colandrea; Stefano Papi; Giuseppe Valmadre; Nicola Fazio; Domenico Galetta; Giovanni Paganelli; Chiara Maria Grana
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-09-21       Impact factor: 9.236

10.  Is 68Ga-DOTATATE the answer in lung carcinoid? : Case report and review of literature.

Authors:  Amit Bhoil; Bhagwant R Mittal; Shankaramurthy Gayana; Raghava Kashyap; Anish Bhattacharya; Navneet Singh
Journal:  Lung India       Date:  2012-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.